DK1064027T3 - APO-2 Ligand-anti-her-2-antistofsynergier - Google Patents

APO-2 Ligand-anti-her-2-antistofsynergier

Info

Publication number
DK1064027T3
DK1064027T3 DK99915054T DK99915054T DK1064027T3 DK 1064027 T3 DK1064027 T3 DK 1064027T3 DK 99915054 T DK99915054 T DK 99915054T DK 99915054 T DK99915054 T DK 99915054T DK 1064027 T3 DK1064027 T3 DK 1064027T3
Authority
DK
Denmark
Prior art keywords
apo
synergies
antibody
ligand
ligand anti
Prior art date
Application number
DK99915054T
Other languages
English (en)
Inventor
Avi J Ashkenazi
Gail D Phillips
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DK1064027T3 publication Critical patent/DK1064027T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK99915054T 1998-03-27 1999-03-26 APO-2 Ligand-anti-her-2-antistofsynergier DK1064027T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7968398P 1998-03-27 1998-03-27
PCT/US1999/006673 WO1999048527A1 (en) 1998-03-27 1999-03-26 Apo-2 ligand-anti-her-2 antibody synergism

Publications (1)

Publication Number Publication Date
DK1064027T3 true DK1064027T3 (da) 2008-09-08

Family

ID=22152138

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99915054T DK1064027T3 (da) 1998-03-27 1999-03-26 APO-2 Ligand-anti-her-2-antistofsynergier

Country Status (14)

Country Link
US (5) US20020141993A1 (da)
EP (1) EP1064027B1 (da)
JP (2) JP2002507404A (da)
AT (1) ATE398464T1 (da)
AU (3) AU765003B2 (da)
CA (1) CA2324494A1 (da)
CY (1) CY1108320T1 (da)
DE (1) DE69938923D1 (da)
DK (1) DK1064027T3 (da)
ES (1) ES2308836T3 (da)
HK (1) HK1034040A1 (da)
IL (2) IL138034A0 (da)
PT (1) PT1064027E (da)
WO (1) WO1999048527A1 (da)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6284236B1 (en) 1995-06-29 2001-09-04 Immunex Corporation Cytokine that induces apoptosis
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
US20040013667A1 (en) * 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US6949245B1 (en) * 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US20030086924A1 (en) * 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US6627196B1 (en) 1999-08-27 2003-09-30 Genentech, Inc. Dosages for treatment with anti-ErbB2 antibodies
EP1263780A2 (en) 2000-01-25 2002-12-11 Genentech, Inc. Liv-1 related protein, polynulceotides encoding the same and use thereof for treatment of cancer
AU2001259271A1 (en) * 2000-04-28 2001-11-12 Millennium Pharmaceuticals, Inc. 14094, a novel human trypsin family member and uses thereof
KR101135233B1 (ko) * 2000-05-19 2012-04-12 제넨테크, 인크. ＥｒｂＢ 길항제에 의한 암 치료요법에 대한 효과적인 반응의 가능성을 개선시키기 위한 유전자 검출 분석
DE10034607A1 (de) * 2000-07-20 2002-02-07 Gundram Jung Multispezifisches Reagenz zur selektiven Stimulierung von Zelloberflächenrezeptoren
DK1303293T3 (da) * 2000-07-27 2009-03-30 Genentech Inc Sekventiel indgivelse af CPT-11 og APO-2L-polypeptid
US20060062786A1 (en) * 2000-11-08 2006-03-23 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US20030228309A1 (en) * 2000-11-08 2003-12-11 Theodora Salcedo Antibodies that immunospecifically bind to TRAIL receptors
US7361341B2 (en) * 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US20050129616A1 (en) * 2001-05-25 2005-06-16 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US20050214209A1 (en) * 2001-05-25 2005-09-29 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
JP2005521640A (ja) 2001-11-13 2005-07-21 ジェネンテック・インコーポレーテッド Ａｐｏ−２リガンド／ＴＲＡＩＬ製剤
US7741285B2 (en) 2001-11-13 2010-06-22 Genentech, Inc. APO-2 ligand/trail formulations
AU2002361784A1 (en) * 2001-12-20 2003-07-09 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
US8124085B2 (en) * 2004-05-05 2012-02-28 Merrimack Pharmaceuticals, Inc. Bispecific binding agents for modulating biological activity
SV2006002143A (es) * 2004-06-16 2006-01-26 Genentech Inc Uso de un anticuerpo para el tratamiento del cancer resistente al platino
JP2008507520A (ja) 2004-07-22 2008-03-13 ジェネンテック・インコーポレーテッド Ｈｅｒ２抗体組成物
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CA2587519A1 (en) * 2004-12-07 2006-06-15 Genentech, Inc. Selecting patients for therapy with a her inhibitor
TWI441646B (zh) 2005-01-21 2014-06-21 Genentech Inc 帕妥珠單抗(pertuzumab)用於製備治療人類病患癌症之藥物的用途
ES2440481T3 (es) * 2005-02-23 2014-01-29 Genentech, Inc. Prolongación del tiempo hasta la progresión de la enfermedad o supervivencia en pacientes de cáncer de ovario usando pertuzumab
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
PE20070207A1 (es) 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
AU2006339445A1 (en) 2006-03-02 2007-09-07 Agency For Science, Technology And Research Methods for cancer therapy and stem cell modulation
WO2008109440A2 (en) 2007-03-02 2008-09-12 Genentech, Inc. Predicting response to a her dimerisation inhibitor based on low her3 expression
US8557588B2 (en) * 2007-03-27 2013-10-15 Schlumberger Technology Corporation Methods and apparatus for sampling and diluting concentrated emulsions
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
ES2417148T3 (es) 2007-06-08 2013-08-06 Genentech, Inc. Marcadores de expresión génica de la resistencia tumoral al tratamiento con inhibidor de HER2
WO2009058102A1 (en) * 2007-11-02 2009-05-07 Agency For Science, Technology And Research Methods and compounds for preventing and treating a tumour
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
CN104447995A (zh) 2009-03-20 2015-03-25 霍夫曼-拉罗奇有限公司 双特异性抗-her抗体
EP2435071A1 (en) 2009-05-29 2012-04-04 F. Hoffmann-La Roche AG Modulators for her2 signaling in her2 expressing patients with gastric cancer
RU2609658C2 (ru) * 2009-12-21 2017-02-02 Дженентек, Инк. Состав, содержащий антитело
CN102892779B (zh) 2010-02-18 2016-12-21 基因泰克公司 神经调节蛋白拮抗剂及其在治疗癌症中的用途
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
EP3539988A3 (en) 2010-05-27 2019-12-04 Genmab A/S Monoclonal antibodies against her2
EP2575880B1 (en) 2010-05-27 2019-01-16 Genmab A/S Monoclonal antibodies against her2 epitope
EP2643353A1 (en) 2010-11-24 2013-10-02 Novartis AG Multispecific molecules
WO2012085111A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
AU2012245116A1 (en) 2011-04-20 2013-11-07 Genmab A/S Bispecific antibodies against HER2 and CD3
BR112014003431A2 (pt) 2011-08-17 2017-06-13 Genentech Inc anticorpo, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, agente farmacêutico, uso do anticorpo, método de tratamento de um indivíduo que tem câncer e método de aumento de tempo para recorrência de tumor
CN104334189A (zh) 2011-10-14 2015-02-04 霍夫曼-拉罗奇有限公司 Her2二聚化抑制剂帕妥珠单抗的用途和包含her2二聚化抑制剂帕妥珠单抗的制品
WO2013063229A1 (en) 2011-10-25 2013-05-02 The Regents Of The University Of Michigan Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells
AU2012346540C1 (en) 2011-11-30 2019-07-04 Genentech, Inc. ErbB3 mutations in cancer
EP2788500A1 (en) 2011-12-09 2014-10-15 F.Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
JP2015514710A (ja) 2012-03-27 2015-05-21 ジェネンテック， インコーポレイテッド Ｈｅｒ３阻害剤に関する診断及び治療
KR102023401B1 (ko) * 2012-05-10 2019-11-04 바이오아트라, 엘엘씨 다중-특이적 모노클로날 항체
CA2889298C (en) 2012-11-30 2024-01-02 Anton Belousov Identification of patients in need of pd-l1 inhibitor cotherapy
NZ751877A (en) 2013-04-16 2020-04-24 Genentech Inc Pertuzumab variants and evaluation thereof
WO2015164665A1 (en) 2014-04-25 2015-10-29 Genentech, Inc. Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab
TWI758784B (zh) 2014-09-12 2022-03-21 美商建南德克公司 抗her2抗體及免疫結合物
CN107124870A (zh) * 2014-09-17 2017-09-01 基因泰克公司 包含抗her2抗体和吡咯并苯并二氮杂*的免疫缀合物
CN107614015A (zh) 2015-05-30 2018-01-19 豪夫迈·罗氏有限公司 治疗her2阳性局部晚期或先前未治疗的转移性乳腺癌的方法
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
US20190151346A1 (en) 2016-05-10 2019-05-23 INSERM (Institute National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer
AU2017355432A1 (en) 2016-11-04 2019-05-16 F. Hoffmann-La Roche Ag Treatment of HER2-positive breast cancer
TW201827077A (zh) 2016-12-28 2018-08-01 美商建南德克公司 晚期her2表現癌症之治療
SI3570884T1 (sl) 2017-01-17 2021-02-26 Genentech, Inc. Subkutane formulacije protiteles HER2
US11077189B2 (en) 2017-03-02 2021-08-03 Genentech Inc. Adjuvant treatment of HER2-positive breast cancer
EP3615695A1 (en) 2017-04-24 2020-03-04 Genentech, Inc. Erbb2/her2 mutations in the transmebrane or juxtamembrane domain

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5720937A (en) * 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP0656367A1 (en) * 1991-08-22 1995-06-07 Becton, Dickinson and Company Method and composition for cancer therapy and for prognosticating responses to cancer theraphy
US5587458A (en) * 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
JP4435304B2 (ja) * 1995-06-29 2010-03-17 イミュネックス・コーポレーション アポトーシスを誘導するサイトカイン
US5783186A (en) * 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US6030945A (en) * 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
EP1003864A1 (en) * 1997-08-15 2000-05-31 Idun Pharmaceuticals, Inc. Trail receptors, nucleic acids encoding the same, and methods of use thereof

Also Published As

Publication number Publication date
WO1999048527A1 (en) 1999-09-30
US20050244417A1 (en) 2005-11-03
US20080241146A1 (en) 2008-10-02
CA2324494A1 (en) 1999-09-30
CY1108320T1 (el) 2014-02-12
AU2010201871A1 (en) 2010-05-27
ATE398464T1 (de) 2008-07-15
IL138034A0 (en) 2001-10-31
ES2308836T3 (es) 2008-12-01
US20020141993A1 (en) 2002-10-03
US20080160026A1 (en) 2008-07-03
IL138034A (en) 2007-12-03
JP2002507404A (ja) 2002-03-12
AU2003266765A1 (en) 2004-01-15
PT1064027E (pt) 2008-09-29
EP1064027B1 (en) 2008-06-18
DE69938923D1 (de) 2008-07-31
HK1034040A1 (en) 2001-10-12
US20070026001A1 (en) 2007-02-01
EP1064027A1 (en) 2001-01-03
AU765003B2 (en) 2003-09-04
JP2010088438A (ja) 2010-04-22
AU3365999A (en) 1999-10-18

Similar Documents

Publication Publication Date Title
DK1064027T3 (da) APO-2 Ligand-anti-her-2-antistofsynergier
CO5640147A2 (es) Metodos y composiciones para inducir apoptosis de cedulas cancerosas
ATE362985T1 (de) Apo-2 ligand
DK1289559T3 (da) Kombinationer af enzyminhibitor-holdige præparater samt anvendelse deraf
ATE330972T1 (de) Apo-2l rezeptor-agonist und cpt-11 synergie- effekt
DK0993831T3 (da) Forbindelser og præparater til tilförsel af aktive stoffer
BR0314814A (pt) Variantes otimizadas de fc e métodos para sua geração
NO993739L (no) Dieseladditiv for aa forbedre cetan, smöreevne og stabilitet
DE69841711D1 (de) Modulator der menschlichen mastzellaktivierung
DK1045906T3 (da) APO-2-ligand
NO20071789L (no) Fremgangsmate for anvendelse av dodsreseptorligander og CD20-antistoffer
BRPI0509177A (pt) uso de anticorpos anti-alfa5beta1 para inibir a proliferação de células cancerìgenas
EA200500206A1 (ru) СПОСОБ И КОМПОЗИЦИИ ДЛЯ МОДУЛЯЦИИ РАЗВИТИЯ И ФУНКЦИИ КЛЕТОК Т-ХЕЛПЕРОВ (Тх)
AR022583A1 (es) Secuencias antitumorales anti-sentido dirigidas contra los componentes r1 y r2 de la reductasa de los ribonucleotidos
SE7806679L (sv) Vattenolosliga enzympreparat och sett for framstellning derav
ATE405282T1 (de) Verwendung von il-13 inhibitoren zur behandlung von tumoren
DK1051187T3 (da) Behandling af follikulære lymfomer ved anvendelse af inhibitorer af lymfotoxin(LT)-syntesevejen
DE69915486D1 (de) Verwendung von eletriptan zur vorbeugung des wiederauftretens der migräne
DK1303293T3 (da) Sekventiel indgivelse af CPT-11 og APO-2L-polypeptid
DK1185279T3 (da) Midler til behandling af maligne sygdomme ved anvendelse af proteinet YB-1
DE69903559D1 (de) Verwendung von neuen zelltod inducierenden mitteln im synergismus mit interferon
EA199901117A1 (ru) Модуляторы путей внутриклеточного воспаления, клеточной гибели и клеточного выживания
DK1171123T3 (da) Fremgangsmåde til behandling af nervecelledöd
FR2395210A2 (fr) Installation pour changement de direction dans une voie transporteuse
ATE329600T1 (de) Verwendung von tagatose zur verbesserung wichtiger blutfaktoren